Overcoming drug resistance in chronic myeloid leukemia

Research output: Contribution to journalReview article

Abstract

Purpose of review: Despite the excellent clinical results with imatinib in chronic myeloid leukemia, most patients have minimal residual disease and others will develop resistance and may eventually progress. Thus there is a need for developing approaches to overcome and prevent resistance to imatinib. Recent findings: Several new agents have been developed with significant activity in imatinib-resistant chronic myeloid leukemia. A second generation of more potent tyrosine kinase inhibitors, some with dual activity against Abl and Src, have shown very impressive results. Other agents, such as hypomethylating agents, farnesyl transferase inhibitors and homoharringtonine, have also shown preclinical and clinical promise. The use of vaccines as a way of providing an immunomodulatory approach to chronic myeloid leukemia is starting to develop as a major strategy to achieve eradication of the disease. Summary: Multiple effective agents are being developed to overcome resistance to imatinib. The challenge for the future is to incorporate them into effective strategies that can eliminate the disease and cure all patients with chronic myeloid leukemia.

Original languageEnglish (US)
Pages (from-to)79-86
Number of pages8
JournalCurrent Opinion in Hematology
Volume13
Issue number2
DOIs
StatePublished - Mar 1 2006
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Drug Resistance
Disease Eradication
Residual Neoplasm
Transferases
Protein-Tyrosine Kinases
Vaccines
Imatinib Mesylate

Keywords

  • Chronic myeloid leukaemia
  • Farnsyl transferase inhibitors
  • Src inhibitors
  • Tyrosine kinase inhibitors
  • Vaccines

ASJC Scopus subject areas

  • Hematology

Cite this

Overcoming drug resistance in chronic myeloid leukemia. / Cortes, Jorge.

In: Current Opinion in Hematology, Vol. 13, No. 2, 01.03.2006, p. 79-86.

Research output: Contribution to journalReview article

@article{43f7b5f4188c423d911a6b5f2c00c66f,
title = "Overcoming drug resistance in chronic myeloid leukemia",
abstract = "Purpose of review: Despite the excellent clinical results with imatinib in chronic myeloid leukemia, most patients have minimal residual disease and others will develop resistance and may eventually progress. Thus there is a need for developing approaches to overcome and prevent resistance to imatinib. Recent findings: Several new agents have been developed with significant activity in imatinib-resistant chronic myeloid leukemia. A second generation of more potent tyrosine kinase inhibitors, some with dual activity against Abl and Src, have shown very impressive results. Other agents, such as hypomethylating agents, farnesyl transferase inhibitors and homoharringtonine, have also shown preclinical and clinical promise. The use of vaccines as a way of providing an immunomodulatory approach to chronic myeloid leukemia is starting to develop as a major strategy to achieve eradication of the disease. Summary: Multiple effective agents are being developed to overcome resistance to imatinib. The challenge for the future is to incorporate them into effective strategies that can eliminate the disease and cure all patients with chronic myeloid leukemia.",
keywords = "Chronic myeloid leukaemia, Farnsyl transferase inhibitors, Src inhibitors, Tyrosine kinase inhibitors, Vaccines",
author = "Jorge Cortes",
year = "2006",
month = "3",
day = "1",
doi = "10.1097/01.moh.0000208468.40991.f2",
language = "English (US)",
volume = "13",
pages = "79--86",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Overcoming drug resistance in chronic myeloid leukemia

AU - Cortes, Jorge

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Purpose of review: Despite the excellent clinical results with imatinib in chronic myeloid leukemia, most patients have minimal residual disease and others will develop resistance and may eventually progress. Thus there is a need for developing approaches to overcome and prevent resistance to imatinib. Recent findings: Several new agents have been developed with significant activity in imatinib-resistant chronic myeloid leukemia. A second generation of more potent tyrosine kinase inhibitors, some with dual activity against Abl and Src, have shown very impressive results. Other agents, such as hypomethylating agents, farnesyl transferase inhibitors and homoharringtonine, have also shown preclinical and clinical promise. The use of vaccines as a way of providing an immunomodulatory approach to chronic myeloid leukemia is starting to develop as a major strategy to achieve eradication of the disease. Summary: Multiple effective agents are being developed to overcome resistance to imatinib. The challenge for the future is to incorporate them into effective strategies that can eliminate the disease and cure all patients with chronic myeloid leukemia.

AB - Purpose of review: Despite the excellent clinical results with imatinib in chronic myeloid leukemia, most patients have minimal residual disease and others will develop resistance and may eventually progress. Thus there is a need for developing approaches to overcome and prevent resistance to imatinib. Recent findings: Several new agents have been developed with significant activity in imatinib-resistant chronic myeloid leukemia. A second generation of more potent tyrosine kinase inhibitors, some with dual activity against Abl and Src, have shown very impressive results. Other agents, such as hypomethylating agents, farnesyl transferase inhibitors and homoharringtonine, have also shown preclinical and clinical promise. The use of vaccines as a way of providing an immunomodulatory approach to chronic myeloid leukemia is starting to develop as a major strategy to achieve eradication of the disease. Summary: Multiple effective agents are being developed to overcome resistance to imatinib. The challenge for the future is to incorporate them into effective strategies that can eliminate the disease and cure all patients with chronic myeloid leukemia.

KW - Chronic myeloid leukaemia

KW - Farnsyl transferase inhibitors

KW - Src inhibitors

KW - Tyrosine kinase inhibitors

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=33646806516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646806516&partnerID=8YFLogxK

U2 - 10.1097/01.moh.0000208468.40991.f2

DO - 10.1097/01.moh.0000208468.40991.f2

M3 - Review article

C2 - 16456373

AN - SCOPUS:33646806516

VL - 13

SP - 79

EP - 86

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 2

ER -